Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Bicycle Therapeutics (BCYC) Equity Average (2018 - 2025)

Bicycle Therapeutics' Equity Average history spans 8 years, with the latest figure at $614.2 million for Q4 2025.

  • For Q4 2025, Equity Average fell 24.36% year-over-year to $614.2 million; the TTM value through Dec 2025 reached $614.2 million, down 24.36%, while the annual FY2025 figure was $701.5 million, 20.54% up from the prior year.
  • Equity Average reached $614.2 million in Q4 2025 per BCYC's latest filing, down from $643.7 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $852.4 million in Q3 2024 to a low of $118.8 million in Q1 2021.
  • Average Equity Average over 5 years is $424.4 million, with a median of $329.5 million recorded in 2022.
  • Peak YoY movement for Equity Average: skyrocketed 184.79% in 2022, then decreased 27.8% in 2023.
  • A 5-year view of Equity Average shows it stood at $258.5 million in 2021, then increased by 8.35% to $280.1 million in 2022, then skyrocketed by 40.46% to $393.5 million in 2023, then soared by 106.38% to $812.0 million in 2024, then dropped by 24.36% to $614.2 million in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Equity Average are $614.2 million (Q4 2025), $643.7 million (Q3 2025), and $704.6 million (Q2 2025).